Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial
British Journal of Ophthalmology · 2026
DOI: 10.1136/bjo-2024-326526 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift British Journal of Ophthalmology, 2026. Verfasst von Hansjuergen T Agostini und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Medical Faculty, University of Freiburg, Freiburg, Germany hansjuergen.agostini@uniklinik-freiburg.de. Hauptthemen laut MEDLINE: Ranibizumab, Receptors, Vascular Endothelial Growth Factor, Recombinant Fusion Proteins, Angiogenesis Inhibitors. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novartis Pharma.
Abstract (Originalsprache)
Background/aims To compare fluctuations of central subfield retinal thickness (CSRT) in patients with neovascular age-related macular degeneration undergoing ranibizumab pro re nata versus aflibercept bimonthly treatment in a prospective 12 month, phase IV, randomised, multicentre study.
Methods
Ranibizumab was administered according to best-corrected visual acuity (BCVA) and/or disease activity detected on spectral domain optical coherence tomography. Aflibercept was administered at three initial monthly visits followed by bimonthly treatment. CSRT stability was evaluated between months 3 and 6. CSRT stability was compared between groups and correlated with functional outcomes at month 12.
Results
Fluctuations of CSRT showed a least-squares (LS) mean (95% CI) difference of −4.12 (−10.22 to 1.98) µm between ranibizumab (25.16 (20.09 to 30.24) µm) and aflibercept groups (29.28 (24.14 to 34.43) µm) (p=0.1850). A predefined analysis of retinal stability, adjusted for baseline CSRT, showed a LS mean (95% CI) difference of −6.53 (−12.47 to −0.58 µm) in favour of ranibizumab (23.53 (18.58 to 28.49) µm) versus aflibercept (30.06 (25.04 to 35.07) µm) (p=0.0315). Pearson’s correlation coefficient demonstrated no correlation between the mean amplitude of CSRT fluctuation between months 3 and 6, and BCVA at month 12 (r = −0.0888). Adverse event rates were low.
Conclusions
Numerical differences in retinal thickness fluctuations between months 3 and 6 were detected between treatment regimens. While the presence of fluctuations has previously been shown to have a negative impact on functional outcomes, our data showed no correlation between the mean amplitude of fluctuations and functional outcomes at month 12.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Medical Faculty, University of Freiburg, Freiburg, Germany hansjuergen.agostini@uniklinik-freiburg.de.
- Department of Ophthalmology, Hospital of the University of Coimbra, Coimbra, Portugal.
- Department of Ophthalmology, University of Bonn, Bonn, Germany.
- Department of Ophthalmology, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
- Department of Ophthalmology, University of Cologne, Cologne, Germany.
- Department of Ophthalmology, Uniklinik Koln, Koln, Germany.
Förderung
- Novartis Pharma
Zitieren
APA
Agostini, H. T., Silva, R., Holz, F. G., Larsen, M., Altay, L., Souied, E. H., Quiering, C., Rose, U., Liakopoulos, S., & SALT study group (2026). Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial. British Journal of Ophthalmology. https://doi.org/10.1136/bjo-2024-326526
Vancouver
Agostini HT, Silva R, Holz FG, Larsen M, Altay L, Souied EH, et al. Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial. British Journal of Ophthalmology. 2026. doi:10.1136/bjo-2024-326526
BibTeX
@article{Agostini2026,
author = {Agostini, Hansjuergen T and Silva, Rufino and Holz, Frank G and Larsen, Michael and Altay, Lebriz and Souied, Eric H and Quiering, Claudia and Rose, Uwe and Liakopoulos, Sandra and SALT study group, SALT study group},
title = {Impact of retinal thickness fluctuations with ranibizumab versus aflibercept in neovascular age-related macular degeneration (SALT): 12-month results from a multicentre, randomised, phase IV trial},
journal = {British Journal of Ophthalmology},
year = {2026},
doi = {10.1136/bjo-2024-326526}
}
EUVIMED